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Abstract
Background: The UK introduced the 7-valent pneumococcal conjugate vaccine (PCV7) into the national vaccination
program in September 2006. Previous modelling assumed that the likely impact of PCV7 on invasive pneumococcal disease
(IPD) would be similar to the US experience with PCV7. However, recent surveillance data show a more rapid replacement of
PCV7 IPD cases by non-PCV7 IPD cases than was seen in the US.
Methods and Findings: A previous model of pneumococcal vaccination was re-parameterised using data on vaccine
coverage and IPD from England and Wales between 2006 and 2009. Disease incidence was adjusted for the increasing trend
in reported IPD cases prior to vaccination. Using this data we estimated that individuals carrying PCV7 serotypes have much
higher protection (96%;95% CI 72%-100%) against acquisition of NVT carriage than the 15% previously estimated from US
data, which leads to greater replacement. However, even with this level of replacement, the annual number of IPD cases
may be 560 (95% CI, -100 to 1230) lower ten years after vaccine introduction compared to what it may have been without
vaccination. A particularly marked fall of 39% in children under 15 years by 2015/6 is predicted.
Conclusion: Our model suggests that PCV7 vaccination could result in a decrease in overall invasive pneumococcal disease,
particularly in children, even in an environment of rapid replacement with non-PCV7 serotypes within 5 years of vaccine
introduction at high coverage.
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Introduction
Pneumococcal disease is a major cause of morbidity and
mortality in young children, the elderly and those with underlying
chronic conditions such as asplenia and immunosuppression.
Polysaccharide vaccines covering 23 of the most prevalent
pneumococcal serotypes (PPV23) provide limited protection
against invasive pneumococcal disease (IPD) and have not had a
major impact on the overall burden of pneumococcal- attributable
disease in those targeted for vaccination [1]. Moreover PPV23
does not protect against acquiring carriage of Streptococcus
pneumoniae, and hence provides no indirect protection in the
unvaccinated. Highly immunogenic pneumococcal conjugate
vaccines in which the polysaccharide antigens are covalently
linked with a protein provide superior protection against IPD and
also reduce carriage of vaccine type (VT) organisms thus
generating herd immunity against VT disease in unvaccinated
groups. Reduction in carriage of VT organisms can however lead
to an increase in carriage of non-VT (NVT) organisms – a
phenomenon known as serotype replacement [2,3].
A seven-valent pneumococcal conjugate vaccine (PCV7),
providing protection against serotypes 4, 6B, 9V, 14, 18C, 19F
and 23F was introduced into the routine childhood immunisation
programme in the United States (US) in 2000 and was shown to
reduce the incidence of VT IPD in all age groups with little NVT
replacement disease [4]. Based on the favourable US experience a
number of countries have now introduced PCV7, including the
United Kingdom (UK) where since September 2006 PCV7 has
been given at 2, 4 and 13 months with an initial catch up
immunisation programme up to two years of age. The likely
impact of PCV7 in the UK was initially evaluated using a dynamic
transmission model with vaccine impact parameterised on the
basis of post-PCV7 IPD data from the US. This model predicted
elimination of VT IPD with limited serotype replacement such
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groups [5]. However, the post-PCV7 experience in England and
Wales showed more aggressive serotype replacement than
reported in the US with consequently less impact than expected
on the overall incidence of IPD [6]. Similar increases in NVT IPD
which have largely negated the reduction in VT IPD have been
reported elsewhere [7,8].
Given the different post-PCV7 experience in the UK, we have
used the national surveillance data on IPD from the first three
years post- PCV7 introduction in England and Wales to re-
estimate key parameters for the dynamic transmission model. One
of the most important is the competition parameter which reflects
the extent to which carriage of one serotype protects against
acquisition of another. If there is little protection against
pneumococcal co-colonisation when carrying VT organisms then
their removal from carriage will have little effect on acquisition
and carriage of NVT and little propensity for serotype
replacement. Conversely, if the protection against pneumococcal
co-colonisation when carrying VT organisms is high then their
removal from carriage has the potential to increase the acquisition
and carriage of NVT pneumococci, which will subsequently be
manifest as replacement disease. The competition parameter is
derived from the observed changes in VT and NVT IPD before
and after PCV7 introduction. Also, since the UK PCV7
programme, unlike that in the US, rapidly achieved high coverage
both in the routine and the catch up programme, we fitted the
model using the actual age-specific coverage data for eligible
monthly birth cohorts achieved by the programme. We used the
re-parameterised dynamic transmission model to predict the long
term impact of the PCV7 programme on the incidence of VT and
NVT IPD by age in England and Wales.
Methods
Model structure
The pneumococcal transmission model describes the dynamics
of carriage of S. pneumoniae, with the resultant expression as IPD
dependent on the case:carrier ratio.(i.e the propensity to cause
disease if carried) which varies between serotypes [9,10]. The
model consists of a set of differential equations that describe the
transmission and clearance of carriage (Figure 1A). A Susceptible-
Infected-Susceptible (SIS) type model was assumed with no natural
immunity to subsequent infection after clearing carriage. Individ-
uals infected by a VT organism could be co-infected by a NVT
Figure 1. Flow diagrams of the pneumococcal transmission dynamics model structures for pre- and post- PCV7 introduction. Sus:
susceptibles, VT: PCV7 type carriers, NVT: non-PCV7 type carriers, Both: both carrying VT and NVT. A) Pre-PCV7 or Unprotected group, B) Partially
Protected, C) Fully Protected, and D) Movements between three groups (A, B and C) through vaccination and waning. The r parameters are age-
dependent recovery rates, lambdas are forces of infection, and cN and cV are competition parameters. The VEc for Partially and Fully Protected groups
are denoted as dP and dF respectively.
doi:10.1371/journal.pone.0026190.g001
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of compartments: susceptibles (non-carriers); VT (VT carriers);
NVT (NVT carriers); both (carriers of both VT and NVT).
Carriers are able to transmit infection of the same type (VT or
NVT) to a susceptible individual at a rate determined by the rate
of physical contacts between individuals in six age groups (,2, 2–
4, 5–9, 10–19, 20–39, and 40+) in the UK estimated in the
POLYMOD diary-based survey of contacts [11], as well as the risk
of transmission per contact. Sensitivity analysis conducted on the
frequency of contacts used in the model was performed by using all
contacts (rather than just physical contacts) from the POLYMOD
study. The wider age band of over 40 is necessitated by the small
number of positive samples in the carriage data in older
individuals [12]; a similar low carriage prevalence was shown in
a carriage study conducted among elderly cohorts in Sydney,
Australia [13]. The risk of transmission per contact is unknown
and was determined by fitting to data (see below). Since the risk
may depend on the age of the infected individual, up to 12
parameters may be employed (6 probabilities for six age groups in
each PCV7-related serotype groups (VT or NVT)). Four different
models were constructed with the following number of parameters
governing this risk: (i) two (assuming the same risks for all age
groups), (ii) four (assuming children under 2 years old have
different risks), (iii) six (assuming stratification into ,2, 2-4 and 5+
year olds), (iv) eight (assuming stratification into ,2, 2–4, 5–9 and
10+ year olds). Individuals in the population can be unprotected
(Figure 1A), partially protected (Figure 1B) or fully protected
(Figure 1C) by vaccination. Children who received one dose under
the age of one year only get partial protection while those who
received at least 2 doses following the first dose under the age of
one and those who received at least 1 dose above the age of one
year get full protection. Vaccine protection for children who
received 2 doses can wane so that the children will belong to either
the Unprotected or the Partially Protected compartments. If these
children receive the third dose at 13 months, they regain the
vaccine protection and become fully protected. This is an
improvement over our previous model [5] which only had two
vaccine protected states, to allow more realistic representation of
actual vaccine uptake in England and Wales. Each month, a
proportion of the remaining unprotected or partially protected
children move to partially protected or fully protected groups
(Figure 1D). Individuals who are partially or fully vaccine
protected gradually lose their protection and move to unprotected
or partially protected compartments respectively, at a waning rate
w (=1/duration of protection) that is constant throughout all ages
and across all compartments. Vaccine protection reduces the
probability of acquiring VT carriage (with efficacy VEc), and the
risk of developing invasive disease following VT carriage (with
efficacy VEd).
The differential equations for the model in Figure 1 are
presented in Figure S1.
Population structure
The population in the model is divided into 100 annual age-
cohorts (0, 1, 2, 3, … , 99). Each annual age-cohort is divided into
48 equal-sized age-cohorts (in total 4800 age-cohorts in the total
population in the model), for the convenience of having four time
steps in each month when using monthly vaccine uptake data.
Individuals are born into the first age-cohort 0, and die after the
last age-cohort 4800. All 4800 age-cohorts begin with a fixed
number of individuals (1000). However, when calculating the force
of infection, the proportion of infected individuals in each
compartment is weighed by the actual number of people in each
age group (based on Office for National Statistics figures from year
2005, i.e. the year immediately prior to the period being
modelled). This ensures a more realistic representation of the
population structure than alternative methods incorporating a
fixed or age-dependent mortality rate (see Figure S2).
Data sources
IPD incidence. The number of reports of IPD to the Health
Protection Agency in the epidemiological year (the beginning of
July to the end of June) before and for three epidemiological years
since PCV7 introduction in England and Wales (up to the end of
June 2009) was used for model fitting. Serotype 1 was excluded as
it has shown large secular changes in incidence in the UK that are
unrelated to PCV7 introduction [6]. Its transmission dynamics
were therefore considered to be affected by factors other than
those represented in the model. In the IPD data set, some cases
were without information on age or serotype. Cases without age
information in the dataset were distributed on the basis of the
annual age distribution of cases with known ages. Then, cases
without serotype information were distributed according to the
annual serotype distribution of typed cases. There was an upward
trend in overall IPD incidence from 2000/01 to 2005/06 before
PCV7 introduction, paralleled by a similar upward trend in
national reports of other bacteraemias [10]. These upward trends
for other bacteraemias have continued post-PCV7 introduction
and are likely to reflect improved ascertainment [6]. Based on
these raw IPD data, an assumption was made that the upward
trend in ascertainment of IPD cases in the pre-PCV7 period would
have continued post-PCV. Age specific IPD rates were therefore
adjusted by estimating the pre-vaccination trend t in total IPD by
linear regression on logged titres (e.g t=1.1 fold change per year)
and inflating the raw incidence rates by a factor of t
x where x is the
number of epidemiological years prior to 2008/09. To obtain 95%
CIs for the corrected rates the lower and upper 95% CI for t was
used where the t values were estimated for six age groups: ,2, 2–4,
5–14, 15–44, 45–64, and 65+. The adjusted IPD cases for two age
groups (, 5 and 65+) are presented in Figure 2 (The full details of
the ascertainment are available in Tables S1 and S2). Since these
data are crucial to model predictions yet subject to an inherently
uncertain ascertainment correction, three scenarios for the
corrected rates were used, based on the point estimate, lower
and upper limits of the 95% CIs.
In the pre-PCV7 use period, VT IPD accounted for 52% of the
total IPD cases (75% for ,5 and 49% for 5+ years). In contrast, in
the third year of PCV7 use, the percentage of total IPD cases
caused by VT was reduced to 20% (11% for ,5 and 21% for 5+
years).
There is no cross protection from the 19F component against
19A as clearly evidenced by the increases in 19A seen in
vaccinated children and older age groups in the UK and
elsewhere. For 6C there is no evidence of cross protection from
the 6B component of PCV7, and for 6A, while there is evidence
for cross protection in vaccinated children against IPD, there is no
evidence of herd immunity induced by cross protection as 6A cases
have increased in older age groups in the UK [6]. We do not
consider that cross protection within serogroups for PCV7 is an
important factor to incorporate in the model.
PCV7 coverage. The numbers of children receiving 0 to 3
doses of PCV7 by month for each monthly age cohort during the
first two years of the PCV7 programme (October 2006 –
September 2008) were obtained from the General Practice
Research Database between October 2006 and September 2008.
The first monthly birth cohort eligible for the routine PCV7
vaccination programme were children born in July 2006. Children
older than this birth cohort but under two years as at September
PCV7 Serotype Replacement Model
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e261902006 were scheduled for the catch-up campaign. Figure 3 presents
the accumulated PCV7 uptake by three doses at the end of the two
years period.
Fitting procedure
The model was fitted to changes in pre- and post-PCV7
pneumococcal disease and carriage for both VT and NVT
serotypes, by varying parameters representing vaccine efficacy
against carriage and disease (for partially and fully protected
individuals), the competition parameter measuring the protection
against acquisition of NVT carriage for someone carrying VT, and
the risk of transmission when a susceptible individual in the
population has a physical contact with an infected individual [4].
Fitting was conducted by comparing (i) model estimates of
pneumococcal carriage at pre-PCV7 equilibrium levels with data
on pneumococcal carriage from a longitudinal swab study carried
out in 2001/2, and (ii) reported IPD cases in the three years since
the introduction of PCV7 (2006/7 to 2008/9). In order to
generate predictions of IPD cases post-vaccination for the second
comparison, case: carrier ratios were estimated for 16 age groups
(,2 m, 2–3 m, 4–5 m, 6–11 m, 1, 2, 3, 4, 5–9, 10–14, 15–24, 25–
44, 45–64, 65–74, 75–84, 85+.), with the prevalence of disease
determined using pre-vaccination data. We assume that the risk of
disease occurs at the time of carriage acquisition [5].
Optimal values of the parameters were obtained by minimising
the Poisson deviance between model estimates and data. A simplex
algorithm [7] (using the fminsearch routine in MATLAB R2006a)
was used to find these parameters. This generated a range of best
fitting models with different numbers of parameters governing the
age-dependent risk of transmission when a susceptible individual
contacts an infected individual. The best fitting of these models
was chosen using Akaike’s Information Criterion (AIC).
An alternative to the directed search approach such as the
simplex algorithm we have used is to use a random search or
Bayesian sampling approach to parameter estimation. This would
produce a range of potential good fitting parameters rather than a
single best fitting set, representing the uncertainty in the data being
fitted to. However, we have taken this uncertainty into account to
some extent, by conducting three separate fits to the midpoint and
endpoints of the 95% uncertainty intervals in the annual number
of IPD cases after adjusting for the pre-vaccination trend.
The model was then used to predict the long term effect of
PCV7 introduction in England and Wales for fifty years after
vaccination begins.
Duration of carriage
As in the previous model, the average duration of carriage was
estimated for the following age classes: 0–1, 2–4, 5–17 and 18+
Figure 2. Raw (filled circles) annual PCV7 type (VT) and non-PCV7 type (NVT) IPD cases for , 5 and 65+ year olds and adjusted IPD
cases (point estimate (solid lines) and 95% confidence intervals (shaded area)) by epidemiological year after correcting for the
underlying upward trend in reporting in each age group.
doi:10.1371/journal.pone.0026190.g002
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17 days in the 18+ age group. Age-dependent recovery rates (1/
average duration of carriage) were assumed to be the same for VT
and NVT (rVi=rNi) due to no significant difference between
these groups [14,16], and also assumed to have the same rates for
vaccinated and unvaccinated individuals. An exponential decay
function of the recovery rates using these durations of infection has
been formulated to provide age-dependent weekly recovery rates.
Results
Best fitting parameters
By fitting models to data, estimates of parameters governing
vaccine efficacy, competition and risk of transmission per contact
were obtained. The most parsimonious model (with the lowest
AIC value) was that with six different age-dependent risks for
transmission per contact, and hence this model was used.
The best fitting parameter for vaccine efficacy against disease
(VEd) was close to 100% for both partially and fully protected
groups (implying that partially and fully vaccinated carriers do not
develop invasive disease). Vaccine efficacy against carriage in
partially protected individuals was insensitive during the fitting
process and was set to 50% of that in fully protected individuals
(reported in Table 1). Hence there was only a single vaccine
parameter (efficacy against carriage in the fully protected group or
VEc) that influences goodness of fit. The best fitting value of the
duration of vaccine protection was strongly correlated with the
best fitting value of VEc; hence it was set to 8.3 years based on the
PCV7 experience in the US [4] whilst the VEc was estimated in
this study. The sensitivity analysis using the lower and upper
boundaries of the duration of PCV7 protection (5 and 20 years)
estimated from Melegaro et al. confirmed that there is only small
difference between overall IPD cases after 10 years of the vaccine
introduction resulted from three different durations (5, 8.3 and 20
years) of PCV7 protection but the fitting results estimated the
degree of vaccine protection differently as the shorter duration of
PCV protection the higher degree.
The best fitting competition parameter from the adjusted IPD
data when the point estimate of the completeness of IPD
ascertainment is used is 0.04 (Table 1) implying that the
individuals with VT carriage have 96% (95% CI 82%-100%)
protection against acquiring NVT carriage compared to
susceptibles.
Results presented in Figure 4 show the carriage prevalence data
of VT and NVT among 10 age groups and their best fitted values
from the fitting model.
Using all contacts (rather than just physical contacts) made little
difference. The best fitting probability of transmission in order to
fit post-PCV-7PCV7 decline in IPD cases decreased because more
contacts per individual were assumed. There was a marginally
Figure 3. Cumulative PCV7 uptake by a number of doses for each birth-monthly age cohort at the end of September 2008 obtained
from the General Practice Research Database.
doi:10.1371/journal.pone.0026190.g003
Table 1. Model deviance and best fitting values for the
competition parameter (cN) and vaccine efficacy against
carriage (VEc) with their 95% CIs based on three scenarios for
the completeness of IPD ascertainment (best-fitting or point
estimate, lower 95% limit of confidence interval and upper
95% limit of confidence interval).
Adjusted Scenarios Deviance VEc 95% CIs cN 95% CIs
Point estimate 711.183 0.52 (0.51,0.56) 0.04 (0,0.18)
Lower 95% CI 709.202 0.51 (0.51,0.52) 0 (0,0.04)
Upper 95% CI 778.631 0.6 (0.56,0.65) 0.37 (0.24,0.47)
doi:10.1371/journal.pone.0026190.t001
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during 10 years of PCV-7PCV7 use) from the long-term
simulations using the mixing matrix with all contacts due to faster
reduction in VT IPD cases but more replacement in NVT IPD
cases.
Case:carrier ratios
The best fitting case:carrier ratios (Figure 5) suggest that
acquisition of VT carriage has a higher risk of causing disease
compared to those acquired NVT carriage for individuals over 6
months of age. They also suggest that the risk of invasive disease
following any pneumococcal carriage acquisition is lower in
individuals aged between 5 and 44 years compared to those aged
,5 and 45+.
Long term incidence
The best fitting model was used to predict the number of IPD
cases expected in England and Wales for the ten years following
PCV7 introduction. Elimination of VT IPD was predicted to
occur within ten years of PCV7 introduction in the UK.
Predicted effect of PCV7 introduction on the number of NVT
IPD cases for ten years after PCV7 introduction. The model
results represent the model fitted to the point estimate for the
number of adjusted IPD cases, with serotype 1 excluded. The
shaded region shows the range of results obtained when the
adjusted number of IPD cases is varied over its 95% CI.
The model suggests that the number of NVT IPD cases may
increase by about 90% (95% CI 63% – 111%) after 10 years of
PCV7 introduction (Figure 6). By the tenth year, the net change in
the annual number of IPD cases (both VT and NVT) is estimated
to be -9% (95% CI -22% - 2%) (Figure 6 and Table 2). The
changes from the previous study are also included in Table 2
describing more reductions on the overall IPD cases due to less
replacement in NVT IPD cases from the lower competition
estimated using the US experience.
PCV7 is predicted to reduce the overall number of IPD cases by
more in younger age groups (Table 2). This is due to both the
direct effect of vaccination (administered to infants, and subject to
waning in older age groups), as well as the higher level of serotype
replacement in older adults as a result of the different distribution
of PCV7 and non-PCV7 serotypes in different age groups. For
instance, the proportion of IPD caused by PCV7 serotypes prior to
PCV7 introduction was 75% in children aged ,5 but only 50% in
65+ year olds.
The best fitting model predicted that there would be 5,700 (95%
CIs, 700-13,000) fewer IPD cases over the first 10 years of
vaccination compared to if PCV7 had not been introduced.
However, if the number of IPD cases is not adjusted for the likely
effects of improving ascertainment, then the best fitting model
would instead predict that PCV7 introduction will cause 1,300
more cases over the same period.
Discussion
Mathematical models have been widely used to investigate the
impact of mass vaccination programmes on the burden of disease,
as well as the cost effectiveness of such interventions [17–21].
Transmission dynamic models of vaccination programmes can
take account of herd immunity effects which are often a major
determinant of the overall population impact of the programme on
disease burden. Such models have been developed to investigate
the dynamics of pneumococcal transmission and the likely effect
on IPD of PCV7 introduction. However, their reliability is
critically dependent on the model structure and assumptions, and
Figure 4. Carriage prevalence reported in the 2001/02 longitudinal swab study and best fitting model fitted values, stratified by
serotype (VT or NVT) and 10 age groups. The model results represent the model fitted to the point estimate for the number of adjusted IPD
cases, with serotype 1 excluded. The best fitting value for the competition parameter (0.04) is assumed here.
doi:10.1371/journal.pone.0026190.g004
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26190Figure 5. Case:carrier ratios of VT and NVT serotypes in 16 age groups for the best fitting model. The model results represent the model
fitted to the point estimate for the number of adjusted IPD cases, with serotype 1 excluded.
doi:10.1371/journal.pone.0026190.g005
Figure 6. The proportional changes and their 95% CI areas of the number of overall and NVT IPD cases per year during the first ten
years of PCV7 use in England and Wales predicted using the adjusted IPD cases with the best fitted ascertainment rate and its 95%
CIs (Lines are for point estimates and shaded area for their 95% CIs).
doi:10.1371/journal.pone.0026190.g006
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fitting. The model described here simulates the long term impact
of the PCV7 programme in England and Wales on VT and NVT
IPD, utilising the best IPD, carriage, vaccine coverage and
population mixing data currently available for this population.
Another limitation of our model is that we did not build natural
immunity into the model structure explicitly due to lack of
information about the natural immunity. However, the assump-
tion of natural immunity was implicitly accounted for by age-
dependent transmission probabilities and case: carrier ratios,
which are consistent with a decreasing probability of acquiring
infection in adults and higher chance of developing IPD in young
children and the elderly population. This method may slightly
overestimate the impact of vaccination (since the parameters are
fixed, whereas natural immunity may decrease if vaccination
reduces the force of infection in children); however, the existence
of natural immunity is so uncertain that it would be equally
difficult to incorporate such an effect.
Despite the added realism in model structure and parameter-
isation, there is necessarily a limit to how far a model such as this
one can be used to simulate reality, given the substantial
differences between individual serotypes in case:carrier ratios,
the potential need to incorporate natural immunity in the
transmission model, together with the need to reflect transition
between different states of vaccine-induced immunity as children
receive their sequential doses in the immunisation course. These
limitations will be particularly exposed when using such models to
investigate the likely impact on IPD of higher valency vaccines
such as the 10-valent (additionally covering serotypes 1, 5 and 7F)
and the 13-valent (additionally covering serotypes 3, 6A and 19A).
However, a model with more compartments representing
individual serotypes and states of immunity would reach the limit
of computational capacity within a compartmental model
framework. Transition to an individual based modelling approach
would seem to be the next logical step in pneumococcal model
development.
Furthermore, the exclusion of serotype 1 from the model was
necessitated by its idiosyncratic behaviour suggesting that the
major determinants of its incidence were not those incorporated in
our model. Secular changes in the incidence of certain serotypes
have been noted in the past [22] and may be influenced by natural
changes in population immunity (possibly induced by carriage) or
possibly changes in the organism that affect its inherent
transmissibility. However, serotype 1 is an important cause of
IPD in adults aged between 5 and 64 years in the UK, and is a
major pathogen in developing countries [23]. When estimating the
likely benefit of higher valency conjugate vaccines that include
serotype 1 it will therefore be important to include serotype 1 in
the overall burden of potentially preventable VT IPD.
The results indicate that PCV7 will eliminate VT transmission
in England and Wales within 10 years. Current VT incidence is
consistent with that prediction [6]. Indeed, post-vaccination
surveillance data from 2009/10 indicate an overall reduction in
IPD of 56% in ,2 year olds and 19% in $65 year olds, even
better than the long-term reduction predicted by the model due to
the recent reduction in IPD caused by serotype 1 (not included in
the model). However, an increase in NVT IPD cases due to
serotype replacement is inevitable. The magnitude of this effect is
dependent on the competition parameter, cN, which reflects the
protection that VT carriers have against acquiring NVT carriage.
Based on the US post PCV7 data, VT carriers were estimated to
have only 15% protection against acquiring NVT infection
suggesting limited serotype replacement in the long term [5].
When using the UK post-PCV7 IPD data, VT carriers were
estimated to have 96% (95% CIs, 72% – 100%) protection against
acquiring NVT infections when compared to those who are
susceptible to VT infections. This strong protection parameter
causes a large replacement of VT by NVT IPD cases (Table 2).
The long-term simulation model suggested PCV7 results in an
overall change in IPD of 29% (95% CIs, 222% - 2%) by 10
years, substantially less than predicted from the previous model
based on the US post PCV7 experience, and with some scenarios
indicating an overall increase in IPD cases. However, the
introduction of PCV13 in 2010 to the UK immunisation schedule
has the potential to limit the increase in non-PCV7 serotypes.
One potential reason for the difference between cN values
estimated from the US and UK post PCV7 data may be the
differences in IPD surveillance systems in two countries [5]. Unlike
the national IPD data set in England and Wales, the US data from
the Active Bacterial Core surveillance (ABCs) includes a
substantial proportion of mild non-hospitalised paediatric cases
who show no evidence of an increase in NVT IPD incidence [4].
When based on hospitalised cases however, the US experience
appears more similar to that in England and Wales in terms of the
absolute incidence and magnitude of increase in NVT IPD. It
would therefore be of interest to parameterise a transmission
dynamic model such as this one using post-PCV7 changes in VT
and NVT IPD in the US just based on hospitalised cases. The
reason for the lack of an increase in the incidence of NVT among
non-hospitalised children in the ABCs system may be a reduction
in the propensity to take a blood culture from those presenting
with perhaps just a fever in the post-PCV7 era.
Several structures have been used in deterministic models in
order to describe pneumococcal transmission and serotype
Table 2. Model estimated proportional change in NVT and overall number of IPD cases from pre- to 10 years post- PCV7
introduction in England and Wales, stratified by six age groups, based on the point estimate of the adjusted number of IPD cases,
and 95% CIs represent the range of results obtained when the adjusted number of IPD cases is varied over its 95% CI.
,5 5–14 15–44 45–64 65+ Total
NVT 136% 74% 87% 87% 87% 90%
95% CI (84%,161%) (55%,94%) (62%,108%) (62%,108%) (62%,108%) (63%,111%)
Melegaro et al. [5] 36% 24% 27% 28% 28% 28%
Overall 242% 226% 3% 21% 27% 29%
95% CI (255%,236%) (234%,217%) (211%,15%) (214%,10%) (220%,3%) (222%,2%)
Melegaro et al. [5] 263% 231% 221% 228% 242% 238%
The proportional changes in NVT and overall IPD cases from best fitted model in the previous study [5] are included for comparison.
doi:10.1371/journal.pone.0026190.t002
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infected states (not infected, carrying VT infection, carrying NVT
infection and co-infected with VT and NVT). Alternative model
structures have been proposed which have the advantage of being
‘‘neutral null models’’ [24], i.e. having no intrinsic mechanism to
promote stable co-existence of strains that are functionally
indistinguishable. Two such models are a triangle model
[24,25](which does not allow co-infection of VT and NVT strains)
and a pyramid model (which allows double infections by the same
serotype group, and clearing of existing infection by a new
infection when carrying double infections) [24]. The triangle
model is unrealistic because many recent longitudinal nasopha-
ryngeal studies with non-conventional methods for serotyping
suggest frequent presence of multiple serotypes in individuals
[26,27]. A pyramid model is very attractive on theoretical grounds,
but non-differentiated carriage data in terms of double infections
from the same serotypes would be a major obstacle to estimating
the parameters such a model for measuring effects of PCV
introduction. We acknowledge that the structure chosen here has
some less attractive features on theoretical grounds (i.e. it is non-
neutral). However, it was chosen on a pragmatic basis, as it allows
a reasonable estimate of the effects of PCV introduction starting
from a non-zero baseline, within the limitations imposed to the
available data.
Apart from the use of the pre- and post-PCV7 IPD data from
England and Wales, there were other differences from the previous
model [5] that were designed to represent more realistically the
demographic and immunisation programmes in England and
Wales. These included the addition of a partially protected group
comprising of children under one year of age in receipt of a single
dose, use of the actual age-specific coverage achieved in the
routine and catch-up programmes, use of data on mixing patterns
from the POLYMOD study rather than being estimated from the
model, and a population structure based on the actual population
of England and Wales. The mixing pattern estimated from the
previous model parameterised with the US IPD data suggested
very strongly assortative mixing (i.e. individuals have contacts
mainly with other individuals in the same age group) while the
POLYMOD data suggests more random mixing which leads to a
greater herd immunity effect. For the population structure, the
classical approaches are either to assume a uniform distribution
with the same size age cohorts (generally from 0-69 years) or a
distribution that uses the natural mortality rate in which the size of
the age cohorts reduces exponentially (Figure S2). Both methods
can result in unrealistic weights for specific age cohorts when
calculating forces of infection, and may cause potential problems
in estimating herd immunity. We used the real UK population
structure in order to minimise these problems, although no
allowance can be made for any future changes in population
structure. These various improvements over the previous model
should produce more accurate model predictions of the short term
effects of the PCV7 programme (eg within the first few years) but
will lead to similar longer-term end points due to the elimination of
the VT carriage which is predicted to occur by year 10 of the
PCV7 programme.
A model such as this that realistically represents herd immunity,
replacement, population age structure and vaccine protection
from both complete and incomplete schedules is important not just
for England and Wales, but also for investigating vaccine impact in
low and middle income settings. Such settings are likely to have
heterogeneous vaccine schedules and fast changing population
structures, with rapid growth in the size of younger age cohorts in
particular. Indeed, an adapted version of this model is currently
being used to inform work commissioned by the World Health
Organization on optimising immunization schedules in low and
middle income countries [28]. The current model, while yet to be
parameterised for such countries, suggests that PCV7 vaccination
can result in a substantial decrease in overall invasive pneumo-
coccal disease in children even in an environment of rapid
replacement with non-PCV7 serotypes. This underlines the
importance of initiatives such as the Global Action Plan to
combat childhood pneumonia with the use of tools such as
pneumococcal conjugate vaccines. Our model can provide
essential information for refining estimates of the cost-effectiveness
of pneumococcal conjugate vaccine introduction, which are
currently largely based on static models that may not accurately
capture the dynamics of herd immunity and serotype replacement.
Supporting Information
Figure S1 Dynamic model structure in equations.
(TIF)
Figure S2 Three methods of representing the age distribution of
the population of England and Wales in mid-2005 (the total size of
the population is the same in all three methods). (1-blue line.
Actual population of England and Wales obtained from the Office
for National Statistics, 2-red line. Rectangular age distribution
assuming equally sized annual age cohorts up to 70 year olds, and
3-green line. Population subject to an age-dependent mortality
rate.)
(TIF)
Table S1 Unadjusted and adjusted (95% confidence intervals)
PCV7 type IPD incidence per 100,000 between 2000/01 and
2008/09 for six age groups with t values.
(DOC)
Table S2 Unadjusted and adjusted (with their 95% confidence
intervals) non-PCV7 type IPD incidence per 100,000 between
2000/01 and 2008/09 for six age groups with t values. IPD cases
due to serotype 1 were excluded.
(DOC)
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